GSK 2302032A

Drug Profile

GSK 2302032A

Alternative Names: GSK2302032A; PRAME Antigen Specific Cancer Immunotherapeutic - NSCLC; PRAME-ASCI-Non-small cell lung cancer

Latest Information Update: 28 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 01 Aug 2016 GSK completes a phase-II clinical trial in Non-small cell lung cancer (Adjuvant therapy) Estonia, France, Germany, Japan, South Korea, Poland, Russia, United Kingdom and USA (NCT01853878)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in France (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in Germany (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top